Dive into the evolving landscape of glioblastoma multiforme surgery with our latest insights on the concept of supratotal resection, a promising approach that is redefining treatment strategies and outcomes.
– by Klaus
Note that Klaus is a Santa-like GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Ultrasound-Guided Resection of High-Grade Gliomas: A Single-Arm Meta-Analysis.
Palavani et al., World Neurosurg 2024
<!– DOI: 10.1016/j.wneu.2024.03.033 //–>
https://doi.org/10.1016/j.wneu.2024.03.033
Ho-ho-ho! Gather around, my curious elves, for a tale not of the North Pole, but of the intricate world of neuro-oncology, where the quest to conquer high-grade gliomas (HGG) unfolds. In this frosty journey, our sleigh is powered not by reindeer, but by the magic of Ultrasound (US), a beacon of hope in achieving the much-coveted Gross Total Resection (GTR) and improving patient outcomes. So, let’s jingle all the way through this meta-analysis, guided by the shining star of PRISMA guidelines, as we explore the enchanted forest of PubMed, Embase, Cochrane, and Web of Science.
Our sack is filled with studies, both randomized trials and observational cohort studies, that shine their lights on intraoperative Ultrasonography (iUSG)-guided resection of HGG. With the help of R software, akin to Rudolph’s red nose guiding us through foggy nights, we delve into statistical analysis, seeking the gift of GTR, while being mindful of the icy patches of subtotal resection and post-resection complications.
In our merry band of 178 patients, the overall rate of GTR achieved with the guidance of iUSG was found to be a jolly 64% (95% CI: 46 – 81%). It appears that the two-dimensional (2D) US, much like the classic Christmas carols, remains dominant at 80% against the newer tunes of US options. However, not all is merry and bright, as complications were reported at a 15% rate (95% CI: 7 – 23%).
Our festive tale concludes with a note that, while we’ve gathered robust data on the utilization of iUSG-guided resection in the battle against HGG, there are still challenges to be addressed. The outcome heterogeneity and limited reporting on complications are like the lumps of coal in our stockings, reminding us of the need for further research. As we look forward to long-term follow-up studies on patient survival and post-surgery quality of life, let’s keep our spirits high and our clinical practices guided by the twinkling lights of existing literature.
And with that, my dear elves, our story comes to an end. May the magic of this season inspire us to continue our quest for knowledge and betterment in the realm of neuro-oncology. Merry Christmas and a Happy New Year!